Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Generic Midamor
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Rehabilitation interventions in multiple sclerosis: an overview.
Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)
Teva Announces U.S. Supreme Court Will Hear Its Appeal on COPAXONE(R) Patent
[A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis].
Imaging robust microglial activation after lipopolysaccharide administration in humans with PET.
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes.
Neuromyelitis optica spectrum disorder: 2-deoxy-2-[(18)f]fluoro-d-glucose positron emission tomography findings.
High-field imaging of neurodegenerative diseases.
Overcoming barriers in progressive multiple sclerosis research.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis.
Early relapses, onset of progression, and late outcome in multiple sclerosis.
Treatment of multiple sclerosis with anti-CD20 antibodies.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Metabolic features of the cell danger response.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Health Canada Approves PLEGRIDY™ (peginterferon beta-1a) for Adults with Relapsing Remitting Multiple Sclerosis

Pages